Vaxcyte (NASDAQ:PCVX) Insider Harpreet Dhaliwal Sells 17,000 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) insider Harpreet Dhaliwal sold 17,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $55.00, for a total value of $935,000.00. Following the transaction, the insider owned 76,756 shares in the company, valued at $4,221,580. The trade was a 18.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte Stock Performance

NASDAQ:PCVX opened at $55.92 on Thursday. Vaxcyte, Inc. has a 1 year low of $29.08 and a 1 year high of $65.00. The stock has a market capitalization of $8.07 billion, a price-to-earnings ratio of -8.13 and a beta of 1.23. The stock has a fifty day moving average price of $53.56 and a two-hundred day moving average price of $55.10.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.06) by $0.09. During the same quarter in the previous year, the company posted ($1.22) earnings per share. On average, analysts predict that Vaxcyte, Inc. will post -7.91 EPS for the current year.

Vaxcyte News Roundup

Here are the key news stories impacting Vaxcyte this week:

• Positive Sentiment: Quarterly loss was narrower than expected: Vaxcyte reported second-quarter EPS of negative $1.97, beating the consensus estimate of negative $2.06. Although the loss widened from negative $1.22 a year earlier, the earnings beat likely helped sentiment. Vaxcyte quarterly earnings release
• Positive Sentiment: Important VAX-31 trial updates are approaching: Topline safety, tolerability and immunogenicity data from the adult Phase 3 OPUS-1 trial are expected in the fourth quarter of 2026. Results from the OPUS-2 and OPUS-3 trials are expected in the first half of 2027, giving investors several potential catalysts. Vaxcyte second-quarter 2026 business update
• Positive Sentiment: Strong liquidity reduces near-term financing risk: Vaxcyte had approximately $2.5 billion in cash, cash equivalents and investments as of June 30, 2026, providing substantial funding for its late-stage vaccine programs and development of VAX-A1.
• Neutral Sentiment: Analyst consensus remains cautious: Brokerages recently assigned Vaxcyte a consensus “Hold” rating, suggesting that valuation, clinical execution and the company’s ongoing losses remain areas of investor concern. Vaxcyte consensus rating report
• Negative Sentiment: Several executives sold shares: The CFO, COO and another insider sold a combined 29,250 shares for approximately $1.6 million. Each transaction was conducted under a pre-arranged Rule 10b5-1 plan, which reduces the significance of the sales but may still weigh modestly on sentiment.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PCVX. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Wall Street Zen lowered shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 28th. Finally, Zacks Research cut shares of Vaxcyte from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $86.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of PCVX. Janus Henderson Group PLC increased its position in shares of Vaxcyte by 23.8% in the 1st quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company’s stock worth $960,231,000 after purchasing an additional 3,188,687 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its position in shares of Vaxcyte by 35.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 11,296,333 shares of the company’s stock worth $521,213,000 after purchasing an additional 2,981,038 shares during the period. Caligan Partners LP acquired a new stake in Vaxcyte in the fourth quarter worth $78,660,000. Adage Capital Partners GP L.L.C. lifted its position in Vaxcyte by 418.0% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,725,000 shares of the company’s stock valued at $79,592,000 after purchasing an additional 1,392,000 shares during the last quarter. Finally, Polar Capital Holdings Plc increased its stake in shares of Vaxcyte by 302.6% in the fourth quarter. Polar Capital Holdings Plc now owns 1,672,783 shares of the company’s stock valued at $77,182,000 after purchasing an additional 1,257,253 shares during the period. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.